Otwarty dostęp

Detection performance and prognostic value of initial bone marrow involvement in diffuse large B-cell lymphoma: a single centre 18F-FDG PET/CT and bone marrow biopsy evaluation study

Andrej Doma

Andrej Doma

  • Department of Nuclear Medicine, Institute of Oncology LjubljanaLjubljana, Slovenia
  • Faculty of Medicine, University of LjubljanaLjubljana, Slovenia
Wyszukaj tego autora
Sciendo|Google Scholar
Doma, Andrej
, 
Katarina Zevnik

Katarina Zevnik

  • Department of Nuclear Medicine, Institute of Oncology LjubljanaLjubljana, Slovenia
  • Faculty of Medicine, University of LjubljanaLjubljana, Slovenia
Wyszukaj tego autora
Sciendo|Google Scholar
Zevnik, Katarina
, 
Andrej Studen

Andrej Studen

  • Experimental Particle Physics Department, Jožef Stefan InstituteLjubljana, Slovenia
  • Faculty of Mathematics and Physics, University of LjubljanaLjubljana, Slovenia
Wyszukaj tego autora
Sciendo|Google Scholar
Studen, Andrej
, 
Veronika Kloboves Prevodnik

Veronika Kloboves Prevodnik

  • Department of Cytopathology, Institute of Oncology LjubljanaLjubljana, Slovenia
  • Faculty of Medicine, University of MariborMaribor, Slovenia
Wyszukaj tego autora
Sciendo|Google Scholar
Prevodnik, Veronika Kloboves
, 
Gorana Gasljevic

Gorana Gasljevic

  • Faculty of Medicine, University of MariborMaribor, Slovenia
  • Department of Pathology, Institute of Oncology LjubljanaLjubljana, Slovenia
Wyszukaj tego autora
Sciendo|Google Scholar
Gasljevic, Gorana
 oraz 
Barbara Jezersek Novakovic

Barbara Jezersek Novakovic

  • Faculty of Medicine, University of LjubljanaLjubljana, Slovenia
  • Division of Medical Oncology, Institute of Oncology LjubljanaLjubljana, Slovenia
Wyszukaj tego autora
Sciendo|Google Scholar
Novakovic, Barbara Jezersek
  
21 lut 2024
Detection performance and prognostic value of initial bone marrow involvement in diffuse large B-cell lymphoma: a single centre 18F-FDG PET/CT and bone marrow biopsy evaluation study's Cover Image
O artykule
Poprzedni artykuł
Następny artykuł
Zacytuj
Pobierz okładkę
Kategoria artykułu: Research Article
Data publikacji: 21 lut 2024
Zakres stron: 15 - 22
Otrzymano: 15 paź 2023
Przyjęty: 03 sty 2024
DOI: https://doi.org/10.2478/raon-2024-0004
Słowa kluczowe
© 2024 Andrej Doma et al., published by Sciendo
This work is licensed under the Creative Commons Attribution 4.0 International License.

FIGURE 1.

Overall survival.
Overall survival.

FIGURE 2.

Gender based survival analysis.
Gender based survival analysis.

FIGURE 3.

International prognostic index (IPI) survival analysis.HR = high risk; HIR = high-intermediate risk; LIR = low-intermediate risk; LR = low risk
International prognostic index (IPI) survival analysis.HR = high risk; HIR = high-intermediate risk; LIR = low-intermediate risk; LR = low risk

FIGURE 4.

Bone marrow involvement status survival analysis.BM = bone marrow
Bone marrow involvement status survival analysis.BM = bone marrow

The six-colour antibody panel used for flow-cytometric immunophenotyping of bone marrow (BM) aspirates

Tube FITC PE PerCP-Cy5,5 APC PE-Cy7 APC-Cy7
1. mAb κ λ CD19 CD5 CD10 CD45
Vé 5 μl 5 μl 5 μl 3 μl 2 μl 3 μl
2. mAb CD34 CD117 CD33 HLA-DR CD14 CD45
Vé 3 μl 3 μl 2 μl 2 μl 3 μl 3 μl
3. mAb CD3 CD56 CD5 CD20 CD19 CD45
Vé 1 μl 3 μl 3 μl 6 μl 3 μl 3 μl
4. mAb CD19 CD45
Vé 5 μl 3 μl
5. mAb FMC7 CD23 CD19 CD5 CD10 CD45
Vé 6 μl 6 μl 5 μl 3μl
6. mAb CD52 CD11c CD19 CD38 CD45
Vé 3 μl 5 μl 5 μl 3 μl 3 μl
7. mAb CD103 CD22 CD19 CD25 CD45
Vé 5 μl 4 μl 5 μl 2 μl 3 μl
8. mAb CD38 CD56 CD19 CD138 CD45
Vé 5 μl 3 μl 5 μl 5 μl 3 μl
9. mAb CD4 CD8 CD3 CD7 CD5 CD45
Vé 3 μl 4 μl 3 μl 2 μl 5 μl 3 μl

Patients’ characteristics

Age (median, range), years 65 (20–79)
Gender, female/male, n (%) 64 (44.1%)/81 (55.9%)
BMI − BMI +
Age (median) [years]; BMI−: BMI+ 66 (25–79) 63(20–78); p = 0.524
Gender, female/male, n; 48/54 16/27; p = 0.277
IPI score, n (%)
IPI Low risk group (LR): 33 (22.8%) 32 1
IPI Low-intermediate risk group (LIR): 32 (22.1%) 22 10
IPI High-intermediate risk group (HIR): 33 (22.8%) 24 9
IPI High risk group (HR): 47 (32.4%) 24 23
Stage at diagnosis, n (%) II: 39 (26.9%)
III: 19 (13.1%)
IV: 87 (60.0%)
Chemotherapy regimen, n (%) R-CHOP: 119 (82.1%)
R-EPOCH: 9 (6.2%)
R-ACVBP: 6 (4.1%)
RCOEP: 3 (2.1%)
Other: 8 (5.5%)
Radiotherapy after chemotherapy, n (%) 52 (35.9%)
Death in 60 months follow-up period, n (%) 29 (20.0%)
Bone marrow involvements present-overall, n (%) 43 (29.7%)
Extranodal sites: 0, n (%) 26 (17.9%)
Extranodal sites: 1, n (%) 48 (33.1%); of those BMI n = 11 (7.6%)
Extranodal sites more than 1, no. (%) 71 (49.0%)
Język:
Angielski
Częstotliwość wydawania:
4 razy w roku
Dziedziny czasopisma:
Medycyna, Medycyna kliniczna, Medycyna wewnętrzna, Hematologia, onkologia, Radiologia
Kanał RSS czasopisma